Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Impel Neuropharma Closes $67.5M Series D Financing
Venture Capital

Impel Neuropharma Closes $67.5M Series D Financing

by vcaonline.com posted 1month ago 19 views
Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson's Disease and Acute Agitation SEATTLE, December 6, 2018-- Impel NeuroPharma ("Impel" or the "Company"), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has completed a Series D financing totaling $67,500,000. The investment is co-led by KKR and Norwest Venture Partners ("Norwest"), with participation from existing investors, Vivo Capital, 5AM Ventures and venBio Partners.

In this article